Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin

JAMA Internal Medicine

Volumn 174, Issue 6, 2014, Pages 947-953

  Davidson, Bruce L ^a   Verheijen, Sara ^b   Lensing, Anthonie W A ^c,d   Gebel, Martin ^c   Brighton, Timothy A ^e   Lyons, Roger M ^f   Rehm, Jeffrey ^g   Prins, Martin H ^h  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f Cancer Care Centers of South Texas   (United States)

^g Fredericksburg Orthopaedic Associates PC   (United States)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; CREATININE; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLEARANCE; CREATININE BLOOD LEVEL; DAILY LIFE ACTIVITY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84902172555     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.946     Document Type: Article

References (20)

1. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):287S-310S. (Pubitemid 39297958)
2. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ?real world? nationwide cohort study. Thromb Haemost. 2011;106(4):739-749.
3. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapywith warfarin, aspirin, and clopidogrel in patientswith atrial fibrillation. Arch Intern Med. 2010;170(16): 1433-1441.
4. Lechat P, Lardoux H, Mallet A, et al; FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. Cerebrovasc Dis. 2001;12(3):245-252.
5. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362-2367. (Pubitemid 39311264)
6. Lane DA, Kamphuisen PW,Minini P, Büller HR, Lip GY. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest. 2011;140(1):146-155.
7. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329(8):524-529. (Pubitemid 23232620)
8. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AG. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation. 1996;94(9):2113-2116. (Pubitemid 26360502)
9. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, LazzariMA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113(5):910-916. (Pubitemid 27216500)
10. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of themitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J AmColl Cardiol. 2000;35(3):739-746. (Pubitemid 30167032)
11. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 1997;350(9075):389-396.
12. HurlenM, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction: theWARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000;34(2):168-171.
13. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE; Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-113. (Pubitemid 34786198)
14. Shorr RI, RayWA, Daugherty JR, GriffinMR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):1665- 1670. (Pubitemid 23217872)
15. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189-192.
16. Chung L, Chakravarty EF, Kearns P,Wang C, Bush TM. Bleeding complications in patients on celecoxib andwarfarin. J Clin Pharm Ther. 2005;30 (5):471-477. (Pubitemid 41603022)
17. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
18. Büller HR, Prins MH, Lensin AW, et al; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
19. WHO Drug Dictionary. Version 2005/Q3. Uppsala, Sweden: Uppsala Monitoring Centre; 2005.
20. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19.